BUSINESS
Asahi Kasei Pharma Licenses Fasudil to Woolsey; Development of Oral Formulation Expected
Asahi Kasei Pharma said on November 25 that it has reached an agreement to license certain rights to the Rho-kinase inhibitor fasudil (Japanese brand name: Eril Injection) to Woolsey Pharmaceuticals, a US company specializing in drug repurposing. As the functions of…
To read the full story
BUSINESS
- AbbVie Japan Launches Skyrizi 55 mg for Pediatric Psoriasis
November 19, 2026
- Japan Drug Makers’ H1 Sales Surge 14.7% as Weak Yen Fuels Growth
November 18, 2026
- Towa, Sawai Grow Sales on Supply Gains; Biosimilars Emerge as New Focus for Others
November 18, 2026
- Kyowa Kirin to Drop Onglyza in First for Originator DPP-4 Inhibitors
November 18, 2026
- Leqembi Sustains Benefits in Early Alzheimer’s after 5 Years of Treatment
November 18, 2026
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…





